<DOC>
	<DOCNO>NCT02404389</DOCNO>
	<brief_summary>This randomize , vehicle control , active comparator , parallel group , study total duration 24 week include screen follow-up . Study drug apply topically 2 cycle 4 week treatment , separate 4 week off-treatment . Assessors study endpoint blind treatment allocation .</brief_summary>
	<brief_title>Safety , Tolerability , Efficacy Study LFX453 Actinic Keratosis Patients</brief_title>
	<detailed_description />
	<mesh_term>Keratosis</mesh_term>
	<mesh_term>Keratosis , Actinic</mesh_term>
	<criteria>At least five ( 5 ) AK lesion within area 25 cm2 , face ( least 2 cm periocular area , lip , naris ear ) and/or bald scalp Presence least one additional visible palpable non hyperkeratotic AK lesion outside select area atopic dermatitis , eczema , psoriasis , rosacea possible confound skin condition face bald scalp Invasive tumor within treatment area Women childbearing potential Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Actinic keratosis , patient , topical , lesion count , clearance rate</keyword>
</DOC>